WANT A PROFILE LIKE THIS?
Create my FREE Plan Or learn about other options
Ning Li
PeerJ Editor
600 Points

Contributions by role

Editor 600

Contributions by subject area

Biochemistry
Cell Biology
Molecular Biology
Internal Medicine
Oncology
Bioinformatics
Gastroenterology and Hepatology
Immunology
Translational Medicine
Biotechnology
Genomics
Diabetes and Endocrinology
Obesity
Pharmacology

Ning Li

PeerJ Editor

Summary

Prof. Li received his Medical Doctorate in 2005 as an outstanding graduate of the Chinese Union Medical University (CUMU). In the same year, he worked in the Department of Thoracic Surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, where he served as an attending physician, deputy chief physician, and was appointed Chief Physician in 2019. He has a solid theoretical foundation and excellent research ability, and has accumulated rich clinical experience during my work. In 2017, he took over as the Director of the Office of Drug Clinical Trial Research Center, and his outstanding achievements in the management of clinical trial institutions and clinical and translational research, and is currently served as the chief expert of China GCP platform and Leading PI of international multicenter clinical trials of anti-cancer drug discovery. He is committed to new anti-tumor drug research, real-world research, full chain translation research of clinical trials, precision treatment of rare tumors and tumor big data research. His H-Index is 44 based on Web of Science. As a sub-project leader of the National 973 Major Project, the National Key R&D Program for Precision Medicine, the National Natural Science Foundation of China, the GCP platform leader, and the leader of the 13th and 14th Five-Year Innovation Project, he has undertaken many research projects.

Biochemistry Biophysics Cell Biology Histology Immunology Molecular Biology Oncology Translational Medicine

Editorial Board Member

PeerJ - the Journal of Life & Environmental Sciences

Work details

Professor

Cancer Hospital of Chinese Academy of Medical Sciences
Clinical Trial Center
Hospital vice president, chief physician, doctoral supervisor In 2005, he graduated from Peking Union Medical College, majoring in Clinical Medicine for eight years. In 2011, he studied tumor immunity, targeting and gene therapy at Harvard Medical School. He introduced the latest international tumor treatment methods and concepts into China, led the research of a variety of new drugs and treatment methods, and was the chief expert of Clinical research (GCP) platform construction of the Chinese Academy of Medical Sciences. Specializes in lung cancer, thymus tumor, malignant mesothelioma, soft tissue sarcoma, small intestine tumor, malignant neurofibroma, neuroendocrine cancer, adrenal cortical cancer and other rare tumors. It is the first to adopt accurate molecular diagnosis for each patient, and individually develop appropriate targeting, cell, antibody, nano, vaccine and other new methods to treat patients with refractory, recurrent or failed tumors. It has won international recognition, and dozens of research articles on new tumor treatment methods have been published in the Lancet Oncology and other top journals, with a total impact factor of more than 400 scores.

Websites

  • ResearchGate
  • Dimensions

PeerJ Contributions

  • Edited 3

Academic Editor on

November 22, 2024
Targeting squalene epoxidase in the treatment of metabolic-related diseases: current research and future directions
Mingzhu Chen, Yongqi Yang, Shiting Chen, Zhigang He, Lian Du
https://doi.org/10.7717/peerj.18522 PubMed 39588004
November 22, 2024
Multifaceted roles of cGAS-STING pathway in the lung cancer: from mechanisms to translation
Mingming Wei, Qingzhou Li, Shengrong Li, Dong Wang, Yumei Wang
https://doi.org/10.7717/peerj.18559 PubMed 39588006
September 13, 2024
The burgeoning spatial multi-omics in human gastrointestinal cancers
Weizheng Liang, Zhenpeng Zhu, Dandan Xu, Peng Wang, Fei Guo, Haoshan Xiao, Chenyang Hou, Jun Xue, Xuejun Zhi, Rensen Ran
https://doi.org/10.7717/peerj.17860 PubMed 39285924